POM

GUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on November 5, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the hearing before the Nasdaq Hearings Panel originally scheduled for November 12, 2026 has been cancelled.

Building a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWD GUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an overview of its strategic evolution and business model transformation amid the rapid development of China's digital healthcare industry. Since its establishment in 2010, Pomdoctor has progressively evolved from the industry's early "traffic monetization" model toward a more diversified and value-oriented healthcare ecosystem, culminating in its current four-tier revenue structure spanning B2C healthcare services, AI-enabled chronic disease management, B2B enterprise and hospital services, and pharmaceutical real-world study ("RWS") and real-world data ("RWD") services.

GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on October 28, 2026, it received two letters (the "Letters") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") regarding deficiencies with respect to certain continued listing requirements of The Nasdaq Global Market. The first Letter notified the Company that, based upon the Company's MVLS for the 30 consecutive business days from September 16, 2026 through October 27, 2026, the Company no longer meets the requirement under Nasdaq Listing Rule 5450(b)(2)(A) to maintain market value of listed securities ("MVLS") of at least $50 million (the "MVLS Requirement").

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today announced that it has commenced to terminate its American Depositary Receipt program (the "ADR Program"), including the termination of the related deposit agreement, as amended, and list the Company's Class A ordinary shares directly on The Nasdaq Stock Market LLC ("Nasdaq"). The termination was previously approved by the board of directors of Pomdoctor on September 3, 2026 and approved by the Company's shareholders on a non-binding advisory basis at the extraordinary general meeting of shareholders held on September 30, 2026.

GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach to health management. For much of the past century, healthcare delivery has primarily followed an event-driven model in which patients seek medical care after symptoms emerge, physicians diagnose the condition, and treatment follows.

GUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that it received a staff determination letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on October 6, 2026. The Letter notified the Company that the closing bid price of the Company's American depositary shares (the "ADSs") had been below $1.00 per share for 30 consecutive business days, from August 24, 2026 through October 5, 2026.

GUANGZHOU, China, Sept. 24, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today highlighted its differentiated "hardware + AI + payment" infrastructure model.

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept.

GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced the formal initiation of its U.S. market entry preparations, marking a decisive advancement in its global growth strategy. As part of the initiative, Pomdoctor has recently commenced recruitment for core U.S.-based leadership and operational roles, completed an initial assessment of the U.S. healthcare market, and begun structuring a dedicated local compliance and regulatory framework.

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement.